Lara Leelaraaa.hashnode.dev·Oct 11, 2024Alibaba's AI-Powered Cancer Detection Tool Recognized on Fortune's 2024 Change the World ListFortune showcases 52 companies making significant social or environmental impacts worldwide. Alibaba’s AI-powered tool outperforms radiologists in spotting pancreatic cancer in non-contrast CT scans. Fortune has named Alibaba Group to its 10th ann...Discusscancer detection tool
Larvol Cliniclarvol.hashnode.dev·Sep 27, 2024Gilteritinib Plus Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia: Phase 3 Study Design and Preliminary ResultsBackground: Gilteritinib is an oral FMS-like tyrosine kinase 3 (FLT3) inhibitor that has demonstrated efficacy with favorable tolerability in patients with FLT3-mutated (FLT3mut+) relapsed/refractory acute myeloid leukemia (AML), including internal t...DiscussCancer
Larvol Cliniclarvol.hashnode.dev·Sep 27, 2024Understanding Distress in Advanced Cancer Patients: A Qualitative Analysis of the P-COCC ValuesBackground: Person-Centered Oncologic Care and Choices (P-COCC) is a validated ACP paradigm of a values-focused patient (pt) interview augmented by an informational care goals video. In a randomized trial (Epstein et al ASCO 2017), P-COCC was accepta...DiscussCancer
Larvol Cliniclarvol.hashnode.dev·Sep 27, 2024Outcomes of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma and Deteriorating Liver FunctionBackground The treatment landscape for patients with unresectable hepatocellular carcinoma (uHCC) has recently expanded. However, there is an unmet need for effective treatment options in patients with Child-Pugh (CP) B liver function. Lenvatinib is ...DiscussCancer
Larvol Cliniclarvol.hashnode.dev·Sep 20, 2024Single-Cell DNA Sequencing Reveals Clonal Dynamics in FLT3-Mutated Acute Myeloid Leukemia during Crenolanib Combination TherapyBackgroundSingle cell RNA (scRNA) sequencing analysis suggests that the presence of FLT3-ITD mutation is associated with a progenitor-like phenotype (1van Galen, et al. Cell, 2019: 176, 1265) while activating mutations in the FLT3 kinase domain are a...DiscussTumor
Larvol Cliniclarvol.hashnode.dev·Sep 20, 2024Phase 3 Trial of Gilteritinib Plus Azacitidine vs. Azacitidine Alone in Newly Diagnosed FLT3-Mutated Acute Myeloid LeukemiaBackground: Gilteritinib is an oral FMS-like tyrosine kinase 3 (FLT3) inhibitor that has demonstrated efficacy with favorable tolerability in patients with FLT3-mutated (FLT3mut+) relapsed/refractory acute myeloid leukemia (AML), including internal t...DiscussTumor
Larvol Cliniclarvol.hashnode.dev·Sep 20, 2024A Phase I Study of a Novel Anti-PD-1 Monoclonal AntibodyPF-06801591 is a humanized IgG4 monoclonal antibody that binds to programmed cell death (PD-1) receptor, blocking its interaction with PD-1 ligands. In a phase I study (NCT02573259; dose-escalation) of 40 patients (pts) with multiple solid tumor type...DiscussTumor
Larvol Cliniclarvol.hashnode.dev·Sep 20, 2024Erlotinib and Proton Therapy for Locally Advanced Pancreatic Cancer: A Phase II TrialPurpose/Objective(s): Epidermal growth factor receptor (EGFR) is overexpressed in pancreatic cancer. EGFR expression plays a potentially important role in modulation of tumor sensitivity to either chemotherapy or radiotherapy. Erlotinib is a receptor...DiscussTumor
Larvol Cliniclarvol.hashnode.dev·Sep 20, 2024SPARC-1: A Phase I Trial of Neoadjuvant IL-1beta and PD-1 Blockade in Localized Renal Cell CarcinomaBackground:Immune checkpoint blockade has significantly improved outcomes for patients with renal cell carcinoma (RCC) in the metastatic setting. However, there is currently no neoadjuvant systemic therapy that improves outcomes for patients with loc...DiscussCancer
Larvol Cliniclarvol.hashnode.dev·Sep 20, 2024Impact of Endocrine Therapy Timing on Disease-Free Survival in Breast Cancer: Insights from the UNIRAD Phase III TrialAbstract Background: Circadian rhythms regulate cellular physiology and could influence the efficacy of endocrine therapy (ET) in breast cancer (BC). We prospectively tested this hypothesis within the UNIRAD adjuvant phase III trial (NCT01805271). Me...DiscussCancer
